Andrea (Flynn) Franson, MD, MS

 Andrea Franson, MD, MS
Clinical Associate Professor
Office:
Department of Pediatrics
D4202 MPB
Ann Arbor, MI 48109-5718
Available to mentor
Andrea (Flynn) Franson, MD, MS
Andrea Franson, MD, MS
Clinical Associate Professor
  • About
  • Links
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications

  • Manage Your Profile

    • About

    Dr. Andrea (Flynn) Franson is a Pediatric Oncologist in the Department of Pediatrics at the University of Michigan. She received her bachelor’s degree from Rensselaer Polytechnic Institute in Troy, New York and her medical degree from the University of Michigan Medical School. She completed her residency in Pediatrics and fellowship in Pediatric Hematology/Oncology at the Children’s Hospital of Philadelphia (CHOP). During fellowship, she earned a master’s degree in Pharmacology from Thomas Jefferson University. She joined as faculty at the University of Michigan in 2019.

    Links
    • twitter

    Qualifications
    • Fellowship
      Children's Hospital of Philadelphia, Pediatric Hematology and Oncology, Philadelphia, United States
      2014 - 2017
    • Clinical Pharmacology Fellow
      Thomas Jefferson University, Pharmacology and Experimental Therapeutics, Philadelphia, United States
      2015 - 2017
    • Residency
      Children's Hospital of Philadelphia, Pediatrics, Philadelphia, United States
      2012 - 2014
    • Internship
      Children's Hospital of Philadelphia, Pediatrics, Philadelphia, United States
      2011 - 2012
    • MS, Pharmacology
      Thomas Jefferson University, 130 S. Ninth Street, Suite 100, Philadelphia, PA, 19107, United States
      2015 - 2017
    • MD
      University of Michigan, Ann Arbor, MI, United States
      2007 - 2011
    • BS
      Rensselaer Polytechnic Institute, Troy, NY, United States
      2003 - 2007

    Center Memberships
    • Center Member
      Rogel Cancer Center

    Research Overview

    Broadly, Dr. Franson's research interests are in the clinical translation of promising therapeutic approaches from the lab into pediatric patients with high-risk brain tumors. She collaborates with several basic science laboratories on campus to move successful compounds or immunotherapies into pediatric and AYA focused clinical trials, with an interest in novel clinical trial designs and the use of PK/PD-informed dosing.

    Recent Publications

     See All Publications
    • Journal Article
      AI-powered segmentation and prognosis with missing MRI in pediatric brain tumors
      Chrysochoou D, Gandhi DB, Adib S, Familiar AM, Vunnava B, Varshochi S, Khalili N, Khalili N, Ware JB, Tu W, Jain P, Anderson H, Haldar S, Storm PB, Franson A, Prados M, Kline C, Mueller S, Resnick A, Vossough A, Davatzikos C, Nabavizadeh A, Kazerooni AF. Npj Precision Oncology, 2026 Dec 1; 10 (1): DOI:10.1038/s41698-025-01269-x
    • Journal Article
      Phase II study of selpercatinib in children and young adults with RET-altered tumors: arm N of the NCI-COG Pediatric MATCH trial (APEC1621N)
      Franson AT, Potter SL, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey BD, Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Ramirez NC, Fox E, Weigel BJ, Hawkins DS, Mooney MM, Takebe N, Tricoli JV, Janeway KA, Seibel NL, Parsons DW. Oncologist, 2026 Nov 1; 31 (11): DOI:10.1093/oncolo/oyag382
      PMID: 42867148
    • Journal Article
      Early increase in apparent diffusion coefficient predicts favorable response to Dordaviprone (ONC201) therapy in H3K27M-mutant diffuse midline glioma.
      Lau BC, Ajaero DP, Hoff BA, Pearson A, Sajjakulnukit P, Wadden J, Adam T, Ji S, Green AL, Nabavizadeh A, Cao Y, Aryal M, Upadhyaya S, Franson A, Galban S, Venneti S, Federowicz B, Shapiro MA, Stuhlmiller TJ, Lyssiotis C, Galban CJ, Parmar HA, Ibrahim M, Koschmann C. Neuro Oncol, 2026 Jul 28; DOI:10.1093/neuonc/noag164
    • Journal Article
      H3K27M enhances basal ATM signaling but is not required for radiosensitization of diffuse midline glioma via ATM inhibition with AZD1390.
      Peterson ER, Parsels LA, Li Z, Zhao X, Hess LD, Guo Y, Messinger D, Parsels JD, Wang Z, Qin T, Valvo VM, Franson AT, Castro MG, Yadav VN, Lawrence TS, Koschmann C, Zhang Q, Wahl DR, Morgan MA. Mol Cancer Ther, 2026 Jul 14; DOI:10.1158/1535-7163.MCT-24-1019
      PMID: 42444560
    • Proceeding / Abstract / Poster
      ID #1008 Trajectory-Based Modeling For Pre-Treatment Prediction of Radiotherapy Response in Diffuse Midline Glioma
      Laslo D, Nguyen TPD, Lerman B, Stoller S, Knowles T, Suhami D, Mir N, Avval AH, Carrion AW, Kline C, Franson A, Müller T, Rauschecker A, Jutzeler C, Mueller S, Brüningk S. Neuro-Oncology Pediatrics, 2026 Jun 25; 2 (Supplement_1): wuag026.442 DOI:10.1093/neuped/wuag026.442
    • Proceeding / Abstract / Poster
      ID #479 Use of Mirdametinib for the Treatment of Neurofibromatosis Type 1–Associated Plexiform Neurofibromas (NF1-PN) in Patients with Prior Mitogen-Activated Protein Kinase (MAPK) Kinase Inhibitor (MEKi) Exposure
      McNall-Knapp R, Foreman N, Franson A, Weintraub L, Bielamowicz K, Nickerson M, Weber M, Lokku A, Bingham R, Vallance K, Hirbe A. Neuro-Oncology Pediatrics, 2026 Jun 25; 2 (Supplement_1): wuag026.172 DOI:10.1093/neuped/wuag026.172
    • Proceeding / Abstract / Poster
      ID #666 Deciphering cellular sates associated with response to dordaviprone (ONC201) in diffuse midline glioma patients from the PNOC022 clinical trial
      Savary C, Vo T, Jackson E, Persson M, Douglas A, McEwen H, McLachlan T, Kline C, Franson A, Waszak S, Nazarian J, Koschmann C, Mueller S, Dun M. Neuro-Oncology Pediatrics, 2026 Jun 25; 2 (Supplement_1): wuag026.267 DOI:10.1093/neuped/wuag026.267
    • Journal Article
      Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma
      Barron T, Drexler R, Mochizuki A, Cantor E, Shamardani K, Soni N, Tlais D, Franson A, Lyons S, Knowles T, Raber S, Mehta V, Quezada MA, Keough MB, Malaki JS, Vo LT, Herrera CE, Taylor K, Ni L, Wu SH, Woo PJ, Ricklefs FL, Schüller U, Mueller S, Fisher PG, Campen CJ, Vogel H, Partap S, Kaila K, Koschmann C, Monje M. Nature Medicine, 2026 Jul 2;

    Featured News & Stories
    Health Lab

    Path forward for glioblastoma treatment

    Experts in brain cancer outline current discoveries and offer a path of hope for glioblastoma treatment
         parents posing in selfie up close with kid in front of them
    Health Lab

    4-year-old pediatric brain cancer patient wins over his care team with cheerful personality

    Pediatric cancer patient at Michigan Medicine was diagnosed with ATRT and underwent chemotherapy and radiation. Four years later, he’s doing well.
         cells spikey on pink background purple spikes
    Health Lab

    New clinical trials for pediatric brain tumors

    Brain and spinal cord tumors account for one in four childhood cancers. Although 75% of children survive for at least five years after being diagnosed, many patients have recurrent tumors that cannot be cured. Andrea Franson discusses current therapies for pediatric brain tumors, how viruses can be used to target tumor cells and the new phase 1 trial that started in May 2025.
    Department News

    Department of Pediatrics Faculty Promotions

    U-M faculty across pediatrics, cardiology, psychology & more were promoted in 2025, recognizing excellence in clinical and academic leadership.
    Department News

    New clinical trials for pediatric brain tumors

    Pediatric brain tumors are tough to treat—new trials use viruses to boost immunity and target recurring cancer cells. Hope is rising.
         An illustration of the inside of a skull with the brain in color
    Illuminate

    A Path of Hope for Glioblastoma Treatment

    The University of Michigan has become a world-renowned institution for treating aggressive brain tumors. From identifying deadly tumors sooner, understanding the biology of how and why they grow, and uncovering promising new treatments, Rogel researchers are carving a path that creates hope for patients, becoming a hub of innovation in the process.